Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302146 | 1.00 | KCNQ2 (0.50) | KCNQ2NPC1RAB9AHTTDHODH | |
| SCHEMBL7125256 | 0.81 | DHODH (0.47) | RAB9ADHODHMEN1KMT2AHPGD | |
| SCHEMBL5914909 | 0.75 | DHODH (0.71) | NPC1RAB9ADHODHMEN1KMT2A | |
| SCHEMBL5914908 | 0.75 | DHODH (0.71) | NPC1RAB9ADHODHMEN1KMT2A | |
| SCHEMBL9597939 | 0.74 | GAA (0.49) | NPC1RAB9AHTTMEN1KMT2A | |
| SCHEMBL21326162 | 0.74 | LMNA (0.46) | KCNQ2NPC1RAB9AHTTMEN1 | |
| SCHEMBL21326166 | 0.74 | LMNA (0.46) | KCNQ2NPC1RAB9AHTTMEN1 | |
| SCHEMBL5186995 | 0.72 | MEN1 (0.68) | KCNQ2NPC1RAB9AHTTMEN1 | |
| SCHEMBL10899897 | 0.71 | DHODH (0.55) | NPC1RAB9ADHODHMEN1KMT2A | |
| SCHEMBL16637119 | 0.70 | DHODH (0.52) | NPC1HTTDHODHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011103016-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | EZH2, BMI1, EZH1 | KCNQ2 4581/4885NPC1 2288/4885RAB9A 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.